Dovonex Psoriasis 50 microgram/g ointment
- Name:
Dovonex Psoriasis 50 microgram/g ointment
- Company:
LEO Pharma
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/07/20

Click on this link to Download PDF directly
LEO Pharma

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 6 July 2020 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 6 July 2020 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
- In section 2 the quantity of propylene glycol has been added
- In section 4.8 the reporting of side effects statement has been updated in accordance with the latest version of Annex 5
Updated on 13 February 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
- Addition of information on alternative format leaflets
Updated on 7 December 2016 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 5.1 and 10 updated as follows;
5.1 Pharmacodynamic properties
ATC Code: D05A X02
Pharmacotherapeutic group: Other antipsoriatics for topical use
Calcipotriol is a vitamin D derivative. In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes. This is the proposed basis for its effect in psoriasis. A clinical improvement usually starts to become apparent after two weeks’ treatment.
10 DATE OF REVISION OF THE TEXT
April 2016 December 2016
Updated on 7 December 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only
Updated on 27 June 2016 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to date of revision
Updated on 27 June 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 17 May 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 13 May 2016 PIL
Reasons for updating
- New PIL for new product